Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics

By LabMedica International staff writers
Posted on 26 Jan 2024

Seegene, Inc. More...

(Seoul, Korea) and Microsoft (Redmond, WA, USA) have entered into a strategic collaboration that opens up a new chapter in the field of molecular diagnostics to realize 'a world free from all diseases and future pandemics'.

Seegene has selected Microsoft as a technology partner for its SG OneSystem business to realize 'a world free from all diseases.' By collaborating with Microsoft to drive the growth of its SG OneSystem business, Seegene has adopted an unprecedented strategy of sharing its unique syndromic quantitative PCR technologies with the world’s leading companies to encourage cross-industry innovation in molecular diagnostics. The expansion of participating companies, with whom Seegene aims to form a global consortium, will empower countries across the world with optimal solutions, enabling them to effectively address future pandemics and collectively move closer to 'a world free from all diseases.'

To achieve this goal, Seegene will work with Microsoft's global healthcare team to help further SG OneSystem's growth by advocating the collective vision, bridging potential partners, and jointly participating in SG OneSystem's annual symposium. Other key events connecting current and prospective SG OneSystem partners, such as a declaration ceremony for scientific communities and other partners participating in the SG OneSystem business will be held within the first half of this year to commemorate the shared vision. Seegene's Digitalized Development System (SGDDS) will integrate Microsoft Azure services, including Azure OpenAI Service, which will be used by Seegene to handle the landscape of data interaction and analysis for researchers dealing with extensive data generated by the SGDDS. The implementation of the highly secure and compliant Azure Trusted Research Environment (TRE) will push the boundaries of PCR research, helping ensure both privacy and regulatory adherence.

Seegene will implement Microsoft Fabric, a single AI-powered analytics platform that will unify Seegene's data and reshape how everyone accesses, manages, and acts on that data with capabilities that span data integration, data engineering, data science, data monitoring, real-time analytics, and business intelligence. The integration of AI-driven assistance through Copilot for Microsoft 365 is expected to accelerate productivity, foster innovation and enhance creativity. Furthermore, Seegene will collaborate with Microsoft on collective healthcare innovation research, including next-generation management and analytics for PCR data, and explore future ventures within the healthcare sector. Seegene aims to improve the healthcare ecosystem with Microsoft by delivering accurate early disease diagnoses that provide the foundation for effective treatment and prevention.

"The strategic collaboration with Microsoft will allow us to have a more structured SG OneSystemTM business model," said Dr. Jong-Yoon Chun, CEO and founder of Seegene. "Through our joint efforts, we expect synergetic effects to pave the way for a world free from all diseases."

"We support Seegene's vision of realizing 'a world free from all diseases,'" added Elena Bonfiglioli, General Manager, Global Health and Life Sciences at Microsoft. "In addition to working with Seegene on its digital transformation, we will collaborate to discover global partners and to further enhance the healthcare ecosystem."

Related Links:
Seegene, Inc.
Microsoft


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automatic CLIA Analyzer
Shine i6000
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.